Skip to main content
. 2016 Dec;25(142):408–417. doi: 10.1183/16000617.0085-2016

FIGURE 1.

FIGURE 1

Macitentan as part of combination therapy significantly reduced the risk of morbidity/mortality events (composite primary end-point) versus placebo in incident and prevalent pulmonary arterial hypertension (PAH) patients. Kaplan–Meier curves for PAH patients receiving background PAH-specific therapy at baseline. HR: hazard ratio. #: log rank. Reproduced and modified from [8] with permission from the publisher.